| __timestamp | Blueprint Medicines Corporation | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 9335772 |
| Thursday, January 1, 2015 | 14456000 | 12390000 |
| Friday, January 1, 2016 | 19218000 | 25602000 |
| Sunday, January 1, 2017 | 27986000 | 21262000 |
| Monday, January 1, 2018 | 47928000 | 28430000 |
| Tuesday, January 1, 2019 | 96388000 | 40849000 |
| Wednesday, January 1, 2020 | 157743000 | 60210000 |
| Friday, January 1, 2021 | 195293000 | 83664000 |
| Saturday, January 1, 2022 | 237374000 | 104097000 |
| Sunday, January 1, 2023 | 295141000 | 106916000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Iovance Biotherapeutics, Inc. over the past decade. From 2014 to 2023, Blueprint Medicines saw a staggering 3,640% increase in SG&A expenses, peaking at $295 million in 2023. In contrast, Iovance Biotherapeutics experienced a more modest 1,045% rise, reaching $107 million in the same year.
Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiency, offering a glimpse into their future trajectories.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Breaking Down SG&A Expenses: AstraZeneca PLC vs Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?